Amphastar Urges 1st Circ. To Nix Rivals' Antitrust Immunity

Law360, New York (December 20, 2016, 8:04 PM EST) -- Amphastar Pharmaceuticals Inc. urged the First Circuit on Monday to revive its suit accusing Momenta Pharmaceuticals Inc. and Sandoz Inc. of trying to block a competing generic version of a blood clot medication, accusing the drugmakers of trying to rewrite a district court decision to hold on to their antitrust immunity.

The specialty drugmaker told the First Circuit that a Massachusetts district court was wrong to conclude that the Noerr-Pennington doctrine protected Momenta from claims that it plotted with Sandoz to keep Amphastar from selling generic...
To view the full article, register now.